戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 lar endothelial cell growth factor (VEGF) in malignant ascites.
2 loid dendritic cells (MDCs) were absent from malignant ascites.
3 CL31, grows robustly, generating exclusively malignant ascites.
4 invasive fluid drainage for the treatment of malignant ascites.
5 eal catheter application in the treatment of malignant ascites.
6                   Such mice began to develop malignant ascites about 6 months after injection, which
7 enge of ovarian cancer is the development of malignant ascites accompanied by widespread peritoneal m
8         Lastly, options for the treatment of malignant ascites, along with future opportunities to us
9  in tumor cells harvested from patients with malignant ascites and in tumor samples taken at a second
10 arian clear cell carcinoma model which forms malignant ascites and solid peritoneal tumors upon intra
11     CS-682 also decreased the development of malignant ascites and the formation of metastases, which
12 is in the tumor microenvironment, we studied malignant ascites and tumors of patients with untreated
13 arization of lesions, decreased formation of malignant ascites, and prolonged survival of mice.
14 omal-derived factor (CXCL-12/SDF)-1 in their malignant ascites, attracting PDCs into the tumor enviro
15 n cancer, were examined from patient derived malignant ascites cells.
16 c cancer (GC) with peritoneal metastases and malignant ascites continues to have poor prognosis.
17                       Treatment of mice with malignant ascites due to mesothelioma with rapamycin led
18 rt the significance of exosomes derived from malignant ascites (EXO(Ascites)) in cancer progression a
19                             We observed that malignant ascites fluid induced potent in vivo neovascul
20  may have clinical application in inhibiting malignant ascites formation in ovarian cancer.
21 etastasis, prolonged survival, and prevented malignant ascites formation.
22  test this novel therapeutic peptide, serous malignant ascites from highly resistant recurrent ovaria
23 d in peritoneal exudate cells (PEC) from the malignant ascites from patients with ovarian cancer.
24 jection of VR cells into athymic mice formed malignant ascites in 100% of the animals when injected i
25 extensively, and produced a larger amount of malignant ascites in IFN-gamma(-/-) mice.
26 intraperitoneal therapy for the treatment of malignant ascites in patients with EpCAM-positive carcin
27 ffects of the CatmAb on the major subsets of malignant ascites-infiltrating leukocytes and the molecu
28                                    Recurrent malignant ascites is a common and challenging condition
29                                              Malignant ascites is a common clinical problem in ovaria
30                                              Malignant ascites is a common complication in the late s
31                                              Malignant ascites is a known consequence of vascular dys
32  correlates with microvessel density, stage, malignant ascites, metastasis, and survival in ovarian c
33 rian carcinoma cell lines and the cells from malignant ascites of chemotherapy-treated patients with
34 toward a safe and effective means to control malignant ascites of EOC.
35 l detachment and in tumor cells derived from malignant ascites of high-grade serous adenocarcinoma pa
36 amniotic fluid, liver cirrhosis ascites, and malignant ascites of ovarian cancer patients.
37 er cells secrete PN, which can accumulate in malignant ascites of ovarian cancer patients.
38                Using cells isolated from the malignant ascites of patients with advanced ovarian canc
39 is in the tumor microenvironment, we studied malignant ascites of patients with untreated ovarian car
40 detected against cells freshly isolated from malignant ascites of previously treated patients.
41              Lastly, in tumor spheroids from malignant ascites or tissues of patients with advanced-s
42 itoneal fluid samples from 258 patients with malignant ascites randomized to catumaxomab or control g
43                                              Malignant ascites resolved in three patients, one each w
44                             Fractionation of malignant ascites revealed that extracellular matrix-deg
45                                Patients with malignant ascites secondary to primary carcinomas benefi
46 in vivo efficacy within the immunosuppressed malignant ascites tissue microenvironment.
47                   Natural fluidic streams of malignant ascites triggered by physiological factors, in
48 nctions to reverse the vascular pathology of malignant ascites using fluid from human patients and an
49 ate macrophages' role in the pathogenesis of malignant ascites, we blocked macrophage function in ID8
50      Analyzing single-cell transcriptomes in malignant ascites, we identified two DGAC subtypes: DGAC
51                       Membrane vesicles from malignant ascites were also found to contain activated M
52                            Tumor biopsies or malignant ascites were collected from patients before tr
53  196 patients, 102 of whom were female, with malignant ascites were included in the study.
54 erous liver metastases and a large amount of malignant ascites, whereas IFN-beta-secreting cells did
55 with recurrent ovarian cancer (OvCa) develop malignant ascites with volumes that can reach > 2 L.